Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.91%
0%
-4.91%
6 Months
-3.39%
0%
-3.39%
1 Year
-6.38%
0%
-6.38%
2 Years
56.53%
0%
56.53%
3 Years
23.22%
0%
23.22%
4 Years
18.28%
0%
18.28%
5 Years
45.78%
0%
45.78%
Eurobio-Scientific SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.04%
EBIT Growth (5y)
-2.69%
EBIT to Interest (avg)
37.35
Debt to EBITDA (avg)
0.21
Net Debt to Equity (avg)
0.02
Sales to Capital Employed (avg)
0.87
Tax Ratio
36.51%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
50.52%
ROE (avg)
25.42%
Valuation key factors
Factor
Value
P/E Ratio
43
Industry P/E
Price to Book Value
1.43
EV to EBIT
21.29
EV to EBITDA
10.89
EV to Capital Employed
1.43
EV to Sales
1.61
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
6.70%
ROE (Latest)
3.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
130.00
152.60
-14.81%
Operating Profit (PBDIT) excl Other Income
23.30
40.60
-42.61%
Interest
4.40
1.30
238.46%
Exceptional Items
-2.00
-0.80
-150.00%
Consolidate Net Profit
4.80
24.90
-80.72%
Operating Profit Margin (Excl OI)
78.00%
203.40%
-12.54%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is -14.81% vs -17.38% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -80.72% vs -58.84% in Dec 2022
About Eurobio-Scientific SA 
Eurobio-Scientific SA
Pharmaceuticals & Biotechnology
Eurobio Scientific SA, formerly Diaxonhit, is a France-based biotechnology company engaged in the field of in-vitro diagnostic. It is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The Company owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. It consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. It has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. It operates through Genbio and Eurobio Capforce Plus.
Company Coordinates 
Company Details
Les Ulis Cedex , LES ULIS None : 91953
Registrar Details






